AbbVie’s Bimatoprost SR glaucoma trial posts Phase 3 results
The completed registry entry concerns duration of effect in open-angle glaucoma or ocular hypertension, not a disclosed efficacy comparison.

AbbVie's Phase 3 Bimatoprost SR trial in open-angle glaucoma or ocular hypertension was listed as completed with results on ClinicalTrials.gov on Nov. 13, 2026.
The update matters because Phase 3 trials are late-stage human studies often used to support regulatory decisions; this registry notice identifies completion and posting status rather than a published efficacy conclusion.
ClinicalTrials.gov identifies the study as NCT03850782 and names AbbVie as sponsor. The trial evaluated the duration of effect of Bimatoprost SR in participants with open-angle glaucoma or ocular hypertension.
Open-angle glaucoma and ocular hypertension are eye conditions linked to pressure-related risk to vision. A sustained-release glaucoma treatment is designed to maintain drug exposure over time, making duration of effect a central clinical question.
Completion of the trial does not by itself show how long Bimatoprost SR worked, how it compared with any comparator, or what adverse events occurred. Those questions require review of the posted outcome and safety data, and any later regulatory or peer-reviewed disclosures.
Source: clinical registry, ClinicalTrials.gov, Nov. 13, 2026
Atlas360 reports health research and does not provide medical advice.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
- NIH-funded researchers map basal ganglia at single-cell resolution
- PFOS levels track 93% higher aggressive breast cancer rate
- Galderma targets Ozempic face with new treatment testing
- Senate passes TBI Act renewal after 2024 lapse
Latest news
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike
- Europe faces attribution gap after 16 cyber, physical incidents

